此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

2026年5月21日 更新者:Innovent Biologics (Suzhou) Co. Ltd.

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBI3005 Combination Therapy in Participants With Advanced Solid Tumors

To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.

研究概览

研究类型

介入性

注册 (估计的)

282

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Has signed a written informed consent form (ICF) and is able to comply with the scheduled study visits and related procedures.
  2. Age ≥ 18 years, irrespective of gender.
  3. Confirmed diagnosis of locally advanced unresectable or metastatic solid tumor.
  4. Expected survival ≥ 12 weeks.
  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
  6. Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days prior to the first study drug administration.
  7. Adequate bone marrow and organ function.

Additional Inclusion Criteria for Cohort 1:

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC.
  2. Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens.
  3. In the safety run-in phase, NSCLC participants who have received prior standard therapy.
  4. In the cohort expansion phase, participants without driver gene mutations who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease.

Additional Inclusion Criteria for Cohort 2:

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic non-squamous NSCLC.
  2. In the safety run-in phase, participants should have received prior standard therapy.

    In the cohort expansion phase:

  3. Cohort 2A: NSCLC participants without driver gene mutations (including at least EGFR, ALK, and ROS1, with written documentation) who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease. Participants who received neoadjuvant/adjuvant therapy are eligible if disease recurrence or progression occurred >6 months after the last neoadjuvant/adjuvant therapy.
  4. Cohort 2B: NSCLC participants with tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens, who have experienced disease progression after prior EGFR-TKI therapy.

Additional Inclusion Criteria for Cohort 3

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC.
  2. Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens.
  3. In the safety run-in phase, participants should have experienced disease progression after prior EGFR-TKI therapy.
  4. In the cohort expansion phase, NSCLC participants who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease. Participants who received neoadjuvant/adjuvant therapy are eligible if disease recurrence or progression occurred >6 months after the last neoadjuvant/adjuvant therapy.

Exclusion Criteria:

  1. Participation in any other interventional clinical study, except for observational (non-interventional) studies or the follow-up period after the end of study treatment in an interventional study.
  2. Prior treatment with antibody-drug conjugate (ADC) drugs bearing a camptothecin or its derivative (topoisomerase I inhibitor) small-molecule payload.
  3. Prior to the first dose of study drug: a) Within 4 weeks: Received intravenous chemotherapy, macromolecular targeted therapy, antibody-drug conjugates, immunotherapy, endocrine therapy, cell therapy, intraperitoneal perfusion chemotherapy, tumor embolization, or interventional chemotherapy. b) Within 2 weeks or 5 half-lives (whichever is shorter): Received oral chemotherapy, small-molecule targeted therapy, or traditional Chinese herbal medicines indicated for anti-tumor treatment. c) Within 4 weeks: Received radical radiotherapy; within 2 weeks: Received palliative radiotherapy. d) Within 2 weeks or 5 half-lives (whichever is shorter): Received strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4). e) Within 4 weeks: Underwent major surgery (craniotomy, thoracotomy, laparotomy, or other surgeries deemed ""major"" by the investigator, excluding puncture biopsy), or has severe unhealed wounds, trauma, or ulcers; within 2 weeks: Underwent laparoscopic exploratory surgery. f) Within 4 weeks: Received live vaccine (mRNA and non-replicating adenovirus vaccines are not considered live vaccines).
  4. Presence of adverse events from prior anti-tumor therapy that have not resolved to Grade 0 or 1 per NCI-CTCAE v5.0 [excluding Grade 2 alopecia, fatigue, pigmentation, insomnia, peripheral neuropathy, hypomagnesemia, and toxicities stably controlled by medication (e.g., hypothyroidism stably controlled by replacement therapy, hypertension with blood pressure stably controlled below 160/100 mmHg by antihypertensive medication)].

Additional Exclusion Criteria for Cohort 1:

  1. History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
  2. History of significant toxicity associated with immune checkpoint inhibitor administration that required permanent discontinuation of such therapy.

Additional Exclusion Criteria for Cohort 2:

  1. History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
  2. History of significant toxicity associated with immune checkpoint inhibitor administration that required permanent discontinuation of such therapy.
  3. History of hemoptysis within 3 months prior to the first dose (blood volume >2.5 mL per cough or cumulative daily hemoptysis >10 mL), or current active bleeding.

Continuous use of aspirin (>325 mg/day) or other non-steroidal anti-inflammatory drugs known to inhibit platelet function within 2 weeks prior to the first dose."

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1:IBI3005+Sintilimab+ Carboplatin+IBI305
注射用双特异性单克隆抗体-喜树碱衍生物偶联物(研发代码:IBI3005)
Anti-PD-1 Monoclonal Antibody
Recombinant humanized anti-VEGF monoclonal antibody
Second-generation platinum-based chemotherapy drugs
实验性的:Cohort 2:IBI3005+Sintilimab+ Carboplatin
注射用双特异性单克隆抗体-喜树碱衍生物偶联物(研发代码:IBI3005)
Anti-PD-1 Monoclonal Antibody
Second-generation platinum-based chemotherapy drugs
实验性的:Cohort 3:IBI3005+Limertinib/Osimertinib
注射用双特异性单克隆抗体-喜树碱衍生物偶联物(研发代码:IBI3005)
Third-generation EGFR-TKI
Third-generation EGFR-TKI

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
总生存期(OS)
大体时间:长达 3 年
长达 3 年
体检结果出现临床显着变化的受试者人数
大体时间:最长 3 年
研究者报告的具有临床意义的异常体检结果。
最长 3 年
生命体征出现临床显着变化的受试者数量
大体时间:最长 3 年
生命体征包括体温、脉搏、呼吸频率、SpO2 和血压
最长 3 年
无进展生存期(PFS)
大体时间:最长 3 年
根据 RECIST v1.1 标准进行评估。
最长 3 年
Number of subjects with adverse events
大体时间:Up to 3 years
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 years
Number of subjects with treatment emergent adverse events
大体时间:Up to 3 weeks
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 weeks
Number of subjects with adverse events of special interest
大体时间:Up to 3 years
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 years
Number of subjects with serious adverse events
大体时间:Up to 3 years
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Up to 3 years
Dose limiting toxicities (DLTs)
大体时间:Up to 3 weeks
Dose limiting toxicities (DLTs) to establish MTD and/or RP2D.
Up to 3 weeks
Number of subjects with clinically significant changes in laboratory tests results
大体时间:Up to 3 years
Clinically significant abnormal laboratory tests results reported by the investigator.
Up to 3 years
Objective Response Rate, (ORR)
大体时间:Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years
duration of response (DCR)
大体时间:Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years
time to response (TTR)
大体时间:Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years
duration of response (DoR)
大体时间:Up to 3 years
as evaluated per the RECIST v1.1 criteria.
Up to 3 years

次要结果测量

结果测量
措施说明
大体时间
抗药物抗体(ADA)
大体时间:最长 3 年
抗药物抗体(ADA)的发生率和特征。
最长 3 年
area under the curve (AUC)
大体时间:Up to 3 years
area under the curve (AUC) of single and multiple doses of IBI3005
Up to 3 years
maximum concentration (Cmax)
大体时间:Up to 3 years
maximum concentration (Cmax) of single and multiple doses of IBI3005
Up to 3 years
time to maximum concentration (Tmax)
大体时间:Up to 3 years
time to maximum concentration (Tmax) of single and multiple doses of IBI3005
Up to 3 years
clearance (CL)
大体时间:Up to 3 years
clearance (CL) of single and multiple doses of IBI3005
Up to 3 years
apparent volume of distribution (V)
大体时间:Up to 3 years
apparent volume of distribution (V) of single and multiple doses of IBI3005
Up to 3 years
half-life (t1/2)
大体时间:Up to 3 years
half-life (t1/2) of IBI3005 to the last administration of IBI3005
Up to 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月1日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2026年5月21日

首先提交符合 QC 标准的

2026年5月21日

首次发布 (实际的)

2026年5月28日

研究记录更新

最后更新发布 (实际的)

2026年5月28日

上次提交的符合 QC 标准的更新

2026年5月21日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • CIBI3005A102

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅